SHP 637
Alternative Names: SHP637Latest Information Update: 29 Aug 2023
At a glance
- Originator Shire
- Developer Takeda
- Class Gene therapies; RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inborn urea cycle disorders
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Inborn urea cycle disorders in Ireland (unspecified route)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Inborn-urea-cycle-disorders in Ireland
- 08 Jan 2019 Shire has been acquired and merged into Takeda